| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm.
Topics include an oral presentation of new 2-year results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improvements in kidney function in adults with chronic hypoparathyroidism treated with TransCon PTH, as well as a symposium presentation on health and quality-of-life improvements in patients switching from rhPTH(1-84) to TransCon PTH as part of a compassionate use program.
"We are pleased to partner with leading experts in endocrinology to present this new, groundbreaking data showing the health and quality-of-life benefits of initiating or switching to TransCon PTH treatment," said Aimee Shu, M.D., Ascendis Pharma's Senior Vice President of Clinical Development, Endocrine Medical Sciences.
The full schedule of Ascendis presentations during ECE 2024 follow:
| Sunday, May 12 2:50 pm (2:40 pm session) Rooms A2-A3 | Oral Presentation Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway Trial Dr. Peter Schwarz |
| Monday, May 13 12:40 – 1:55 pm Room A7 | Symposium
|
Posted In: ASND
